-
Teva's Litigation Risks Weigh Against Stabilizing Fundamentals, Analyst Says
Thursday, August 6, 2020 - 1:22pm | 304Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported strong quarterly results, prompting an analyst at Barclays to upgrade the stock. The Teva Analyst: Balaji Prasad upgraded Teva from Underweight to Equal-Weight and increased the price target from $10 to $13. The Teva Thesis: Teva...